^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Title:

Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors

Published date:
07/22/2020
Excerpt:
...UZLX-GIST9FKIT 11+17 harbored mutations in exons 11 and 17 (p.P577del;W557LfsX5;Y823D)…Expectedly, imatinib treatment resulted in tumor volume reduction in UZLX-GIST3KIT 11, the imatinib-sensitive model with KIT exon 11 mutation, while having no effect on UZLX-GIST9FKIT 11+17, the model with double KIT exon 11 and 17 mutations.
DOI:
https://doi.org/10.1016/j.tranon.2020.100832